Objective: Circulating endothelial progenitor cells (EPCs) are a specialized subset of stem/progenitor cells found in bone marrow. They participate in neo-vascularization of injured vessels and predict cardiovascular outcome in patient at risk. Several factors influence their migration and proliferation, among which is the widely studied stromal-derived factor-1a (SDF-1a). In cardiovascular disease, regarding thoracic aortic aneurysms (TAAs), few studies have investigated the levels of EPC and SDF-1a. As rupture, acute dissection and hematoma are acute complications of idiopathic ascending thoracic aortic aneurysm (iATAA) that increase with the size of aneurysm, we aimed to evaluate a potential relationship between circulating EPC and SDF-1a and iATAA size. Methods: The aneurysm size of 27 consecutive patients suffering from iATAA and scheduled for surgery was assessed by computed tomography scan. In all patients, we measured levels of circulating EPCs by flow cytometer, and plasma levels of SDF-1a the day before surgery. Results: The median aneurysm size was 54 mm (interquartile range (IQR): 50.0-58.8]. The EPC levels of CD34+/CD144+/CD14À and CD34+/VEGFÀR2+/CD14À were inversely correlated to aneurysm diameter ( p = 0.038, r = À0.424 and p = 0.0046, r = À0.65, respectively) before surgery. Conversely, plasma levels of SDF-1a were positively correlated to aneurysm size ( p = 0.042; r = 0.47). Conclusions: Our findings indicate that EPC levels may be useful for monitoring ascending aorta aneurysms and that SDF-1a could be a biomarker of iATAA expansion. #
Introduction
Aortic aneurysm is the 18th cause of mortality in developed countries [1] . The incidence of thoracic aortic aneurysms is nearly 10.4 new cases per 100 000 persons per year [2] . Thoracic aortic aneurysms are essentially degenerative and idiopathic and the molecular and histological mechanisms involving idiopathic ascending thoracic aortic aneurysms (iATAAs) are poorly understood [1] . Several interdependent processes appear to be responsible for the genesis of iATAA in particular, remodeling of the aortic wall, inflammation and angiogenesis, and biomechanical and genetic factors leading to cystic medial degeneration consisting in destruction of the extracellular matrix, with formation of holes filled with mucopolysaccharides [1] . Rupture, acute dissection, and hematoma are acute complications of iATAA. They call for emergency surgical treatment, which may lead to serious complications and an increase in morbidity and mortality. The risk of acute evolution is major beyond a diameter of 6 cm, and surgical sanction is advised as of 5.5 cm or when annual evolution is over 0.5 cm per year [3] . This situation highlights the urgent need for identification of novel cellular or plasmatic biomarkers of iATAA.
In recent years, numerous studies have suggested that stem cells can be used as a biomarker of cardiovascular diseases [4] . Bone marrow is a major source of hematopoietic and endothelial progenitor cells (EPCs) that have common epitopes, mainly CD34 and CD14. Some specialized subsets including CD34+VEGFR-2+ cells, named circulating EPCs, have angiogenesis capacities [5] , are correlated with risk factors for coronary disease [6] and predict cardiovascular outcomes in patient at risk [7] . The homing and trafficking of circulating EPC from bone marrow to peripheral blood is regulated by various mediators. Among them, the stromalderived factor-1a (SDF-1a) is potentially of interest because of its chemotaxis, powerful ability to mobilize, home and engraft stem and progenitor cells [8] . Given the predicted role of circulating EPC in cardiovascular outcomes and the role of SDF-1a in the mobilization of circulating progenitor cells, we aimed to evaluate a relationship between iATAA size and the number of specialized subsets of circulating EPC and the plasma levels of SDF-1a.
Material and methods

Study population
Between December 2008 and February 2010, 27 patients suffering from iATAA underwent scheduled surgical replacement of the ascending aorta in our department. All patients were over 18 years old and provided written informed consent the day before surgery. Exclusion criteria were: aortic aneurysms secondary to genetic syndromes such as Loeys-Dietz, Ehlers-Danlos, and Marfan syndrome, abdominal aortic aneurysm, past or present coronary disease with or without coronary angioplasty, congenital heart disease, stroke, lower limb arteriopathy, active infectious syndrome, auto-immune diseases, past or present treatment by erythropoietin, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), thrombocytopenia, history of renal or hepatic diseases, hematological or coagulative disorders, acute or chronic inflammatory diseases, diabetes mellitus, pregnancy, recent trauma, underlying infection, cancer, and age under 18 years. Every patient underwent surgical graft replacement of the ascending aorta, extended if necessary to the aortic root and/or to the aortic arch. This was sometimes associated with aortic valve surgery. Serum levels of troponin I (TnI), creatine kinase (CK) and creatine kinase isoenzyme myocardial and brain (CK-MB) were determined at admission, and 6 and 12 h after surgical replacement. Creatinine and total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol were also determined at admission. Serum levels of brain natriuretic peptide (BNP), high sensitivity Creactive protein (Hs-CRP), and SDF-1a were measured. An aortic tissue sampling was histologically analyzed after surgery in all patients. The study protocol was approved by the local ethics committee and informed consent was obtained from all enrolled patients.
Aneurysm characteristics
Aneurysm characteristics were assessed by preoperative thoracic scan according to current guidelines [3] . Computed tomography (CT) was performed with a 64-slice scanner (Brillance 64, Philips Healthcare) in all patients. Images were acquired during a single 20-s breath hold, during which the entire thorax was imaged. The CT parameters were set at 0.625-mm detector collimation, 1.4-mm slice thickness, and 0.7-mm reconstruction interval. The scan was started 70-90 s after intravascular injection of 90 ml of non-ionic contrast (Iopamiron 400, Bracco Imaging, France) followed by a 30-ml saline solution at a flow rate of 3.5 ml s À1 . Ascending aorta aneurysm size was assessed by measuring the external diameter at maximum thickness and perpendicular to blood flow. All images were analyzed by the same observer, who took one or two measurements. Another measurement was performed by a second radiologist and, if the results were discordant, the mean of the measurement was assessed.
In vitro study
Peripheral venous blood samples for mononuclear cell (MNC) isolation were drawn preoperatively before drug administering anesthesia either the day before surgery or the day of surgery. Briefly, 20 ml of heparinized blood was diluted with 20 ml of phosphate-buffered saline (PBS). Isolated peripheral blood mononuclear cells (PBMNCs) were then obtained by Hypaque-Ficoll density gradient centrifugation (for more details see Reference [9] ). CD34+CD133+CD14À, CD34+CD146+CD14À, CD34+CD144+CD14À and CD34+VEGF-R2+CD14À were used as markers of EPCs.
Cells were then stained with phycoerythrin (PE), or fluorescein isothiocyanate (FITC), or allophycocyanin (APC), or peridinin-chlorophyll-protein-complex (Per-CP)-conjugated monoclonal antibodies against CD34, CD133 (Miltenyi Biotec, Paris, France), CD146 (Millipore, Molsheim, France), vascular endothelial growth factor-receptor type 2 (VEGF-R2) (R&D, Lille, France), CD144 (Valbiotech, Paris, France), and CD14 (R&D, Lille, France) and analyzed by FACsort flow cytometer (BD Biosciences, Pont de Claix, France) equipped with Cellquest TM software. Isotypic antibodies were used as controls. Plasma levels of SDF-1a were determined on admission using commercially available kits (R&D, Lille, France).
Statistical analysis
Data are expressed as mean values AE standard deviation (SD) or as median with interquartile rang (IQR), as appropriate. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Levels of circulating EPCs and SDF-1a were analyzed after log transformation (on a base 10 scale) to normalize distribution. Pearson correlation ratios were used to correlate circulating progenitor cells and SDF-1a levels to aneurysm diameter. Considering an 80% power calculation, a 0.6 correlation coefficient, and a beta risk at 0.05, 20 patients provided a sufficient sample size for this study. For all analyses, a p value <0.05 was considered statistically significant. Statistical analyses were performed with Windows SAS statistical software, version 9.1-3.
Results
Study population
All operations were scheduled and consisted in surgical replacement of the ascending aorta, sometimes extended to the first or the third segment of the aorta, or to the aortic valve. The study population was predominantly male (88.9%). The mean age was 63.9 AE 12.3 years. Five patients (18.5%) had a body mass index (BMI) over 30 kg m À2 and 15 (55.5%) had hypercholesterolemia. Nineteen patients (70%) had high blood pressure, which was controlled by an anti-hypertensive treatment to obtain a systolic pressure of nearly 120 mmHg. Clopidogrel and vitamin K antagonists were stopped 7 days before surgery. A summary of the baseline characteristics of the study population is shown in Table 1 .
Aneurysm characteristics
The median aneurysm diameter assessed by preoperative scan was 54 mm (IQR: 50.0-58.8) in all patients. The aneurysm was limited to the ascending aorta in 10 cases (37%). In five cases (18.5%), it extended to the aortic arch, and in 12 cases (44%), to the aortic root. The majority of patients were asymptomatic. Ten patients (37%) had an aneurysm larger than 55 mm in diameter, with the largest being 65 mm. Thirteen patients (48%) had a bicuspid aortic valve. In these cases, we did five Bentall procedures, five ascending aorta replacements with aortic valve replacement conserving the aortic root, and three isolated ascending aorta replacement procedures. Histological lesions were predominantly cystic medial degeneration (n = 21; 77%), solitary (n = 12; 44%), or associated with atherosclerotic lesions (n = 9; 33%). Operative and histological data are shown in Table 2 .
Relationship between aneurysm size and phenotypic characteristics of circulating progenitor cells
A combination of anti-CD34, anti-CD144, anti-VEGF-R2, anti-CD133, anti-CD14, and anti-CD146 antibodies was used to select main circulating progenitor cell phenotypes. Anti-CD14 antibody was used to exclude the macrophagic origin of circulating progenitor cells. The levels of circulating CD34+/ CD144+/CD14À, CD34+/VEGF-R2+/CD14À, CD34+/CD133+/ CD14À, and CD34+/CD146+/CD14À and the plasma levels of SDF-1a are shown in Table 1 and Fig. 1 . Among the different phenotypes of circulating progenitor cells, only the blood levels of CD34+/CD144+/CD14À ( p = 0.038, r = À0.44; n = 23) and CD34+/VEGF-R2+/CD14À ( p = 0.0046, r = À0.65; n = 17) cells were significantly correlated with the diameter of the aneurysm (Fig. 2) .
In addition, SDF-1a was significantly correlated with aneurysm diameter ( p = 0.042, r = 0.47; n = 16) (Fig. 2) . However, we found no relationship between SDF-1a and the different phenotypes of progenitor cells.
We found no difference between patients with a tricuspid aortic valve and those with a bicuspid aortic valve either when we compared mean aneurysm diameter or when we looked for a correlation between EPC levels and aneurysm size, and SDF-1a levels and aneurysm size.
Discussion
Few studies have investigated the relationship between EPCs and aortic aneurysms. Moreover, these studies aimed to show the presence or the localization of CD34+ or CD34+CD133+ cells in abdominal aortic aneurysm [10, 11] . To the best of our knowledge, our study is the first to show a relationship between circulating EPCs and the severity of the iATAA, which is reflected by the aneurysm's diameter. The exact mechanism involved in iATAA occurrence is not clear. However, it is commonly admitted that atherosclerosis, the main mechanism of abdominal aortic aneurysm, is not involved in the genesis of iATAA. The risk of acute evolution due to rupture or acute dissection does constitute a serious concern with respect to iATAA. Our study showed that EPCs and, particularly, circulating CD34+CD144+CD14À and CD34+VEGF-R2+CD14À cells could be biomarkers of iATAA severity.
PBMNC population contains both hematopoietic and endothelial progenitors, which can be detected by specific markers. CD14 is known to be a common epitope between committed lineages of hematopoietic (monocytes and macrophages) cells and EPCs [12] , whereas CD34 and CD133 are restricted to their progenitors [13] . In addition, circulating EPCs express CD34, CD133, as well as other stem and endothelial markers, such as CD144 (VE-Cadherine), CD146 (Muc18/S-endo), and VEGF-R2 [14] .
CD34+ cells have been extensively studied in the framework of cell-based therapy. However, while the CD34+ phenotype is common to both hematopoietic cells and endothelial progenitors, it cannot distinguish between these two types of cell. Therefore, the double positive CD34+144+, CD34+146+, CD34+VEGF-R2+, and CD34+CD133+ progenitor cell population with a negative selection for CD14 is commonly accepted and characterizes circulating EPCs [9, 15] . The presence of EPCs has been considered as a protective factor in acute myocardial infarction [16] . Moreover, two major studies have shown the level of EPCs to be inversely related to cardiovascular outcomes [7, 17] . Our findings confirm these data and suggest that the iATAA in patients with a low level of CD34+144+CD14À and CD34+VEGF-R2+CD14À cells is larger in diameter and consequently presents a greater risk of acute complication.
We found no correlation between iATAA size and CD34+CD133+CD14À cells, whereas Dawson et al. reported more CD34+CD133+ cells in patients with abdominal aneurysm [10] . It is difficult to compare our results with those of Dawson et al., as they showed no correlation between aneurysm size and the number of progenitor cells, and their patients had abdominal aortic aneurysm.
These findings should be interpreted with respect to the levels of EPCs in healthy controls, for whom even the number of circulating EPC is extremely variable. Indeed, the number of circulating EPC has been assessed in healthy controls in some studies. Van [19] . These discrepancies highlight the extreme variability of EPCs in a healthy population, depending on the number, age, sex, and the lack of a standardized method for quantifying EPC [20] .
We, along with others, have shown that statins can mobilize EPCs in peripheral blood [9] . In our study, 13 patients were treated with statin; however, the levels of EPCs were the same in patients with or without statins. This observation showed that statins are not sufficient to mobilize EPCs in iATAA patients.
Numerous cytokines known to increase progenitor cell mobilization are markedly up-regulated in acute vascular injury. SDF-1a and its receptor CXCR4 play an important role in progenitor homing to an ischemic myocardium and are thought to facilitate vascular repair [8] .
SDF-1a was originally purified from bone marrow stroma cells and considered as a chemokine that selectively induces the migration of bone marrow progenitor cells, their homing, and differentiation in response to vascular injury [8] . Two recent studies reported similar levels of SDF-1a plasma level in 12 (2405 pg ml À1 ) [21] and 574 (2565 pg ml À1 ) [22] healthy subjects. However, in cardiovascular disease, the levels of SDF-1a are variable when compared with controls. Indeed, a decreased level of SDF-1a has been reported in patients with stable and unstable angina [23] and in ST elevation myocardial infarction (STEMI) patients [24] compared with controls. In chronic heart failure patients, plasma level increased with respect to control [18] . In our study, the mean plasma level of SDF-1a was 2137 pg ml À1 , but due to the lack of a control group and convincing data for the plasma levels of SDF-1a in iATAA, it is particularly difficult to interpret these results. A larger population is needed to reinforce our results. However, the positive correlation between the level of SDF-1a and the diameter of iATAA suggests that the remodeling and vascular injury occurring during iATAA could induce the release of SDF-1a.
Another discrepancy in our study is the lack of significant correlation between plasma levels of SDF-1a and the number of circulating EPC. Xiao et al. [22] , on the other hand, showed that plasma levels of SDF-1a were inversely associated with EPCs in a population-based study. As several studies have shown that SDF-1a plays an important role in mobilizing circulating EPC [8] , we expected to obtain a positive correlation between SDF-1a and circulating EPC. However, our results show no correlation. Our results are in agreement with those of Van Craenbroek et al. and Ratjczak et al., who showed no correlation between an increase in plasma levels of SDF-1a and circulating EPC (CD34+ and CD34+VEGF-R2+) number [18, 25] . Another explanation could be that the number of patients in our study may not have been sufficient to observe such a relationship.
These observations show that SDF-1a is not a good marker to predict the number of circulating EPC in iATAA.
Conclusions
Our study is the first to show the relationship between patients with low levels of EPCs and the diameter of iATAA. In addition, we highlighted the positive correlation between SDF-1a level and iATAA diameter. A better knowledge of the pathophysiology of idiopathic ascending aorta aneurysms could lead to earlier diagnosis and a new follow-up approach after diagnosis, based on circulating EPCs and SDF-1a quantification.
Limitations
This article presents some potential limitations. First, given the type of aneurysm and exclusion criteria, the number of patients enrolled was limited and did not allow an appropriate statistical analysis. A greater number of patients would reinforce this preliminary report. Second, the lack of subsets of circulating EPC in some patients, related to the low rate in peripheral blood, hampers strong correlations. Third, the absence of an age-matched control prevented assessment of an increase or decrease in circulating EPC in iATTA patients; more importantly, no data were available concerning the levels of EPC in iATTA. Finally, these preliminary results require further investigation, particularly with respect to potential endothelial injury and its restorative mechanism in case of iATAA.
